|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300073933 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-25 15:59:21 |
|
注册时间: Date of Registration: |
2023-07-25 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
飞秒激光辅助制瓣LASIK 联合快速交联矫正高度近视安全、有效性临床评价 |
|
Public title: |
Clinical evaluation of safety and effectiveness of femtosecond LASer-assisted flap manufacturing LASIK combined with accelerated crosslinking in correction of high myopia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
FS-LASIK 联合快速交联矫正高度近视安全、有效性临床评价 |
|
Scientific title: |
Clinical evaluation of safety and efficacy of FS-LASIK combined with accelerated crosslinking in correction of high myopia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
季鹏 |
研究负责人: |
季鹏 |
|
Applicant: |
Ji Peng |
Study leader: |
Ji Peng |
|
申请注册联系人电话: Applicant telephone: |
+86 135 7375 3812 |
研究负责人电话:
Study leader's |
+86 135 7375 3812 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ji6605@126.com |
研究负责人电子邮件: Study leader's E-mail: |
ji6605@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
https://www.semeye.com/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
https://www.semeye.com/ |
|
申请注册联系人通讯地址: |
山东省济南市英雄山路48号 |
研究负责人通讯地址: |
山东省济南市英雄山路48号 |
|
Applicant address: |
No. 48, Yingshan Road, Jinan City, Shandong Province |
Study leader's address: |
No. 48, Yingshan Road, Jinan City, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
250002 |
研究负责人邮政编码: Study leader's postcode: |
250002 |
|
申请人所在单位: |
山东中医药大学附属眼科医院 |
||
|
Applicant's institution: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
山东中医药大学附属眼科医院 |
||
|
Affiliation of the Leader: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SDTCMYK201904010 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东中医药大学附属眼科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-03-18 00:00:00 | ||
|
伦理委员会联系人: |
李小鹏 |
||
|
Contact Name of the ethic committee: |
LiXiao-Peng |
||
|
伦理委员会联系地址: |
山东省济南市英雄山路48号 |
||
|
Contact Address of the ethic committee: |
No. 48, Yingshan Road, Jinan City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 5885 9677 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
semkyk@163.com |
|
研究实施负责(组长)单位: |
山东中医药大学附属眼科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市英雄山路48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 48, Yingshan Road, Jinan City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
山东中医药大学附属眼科医院科研基金支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
Scientific research fund of eye hospital affiliated to shandong university of traditional Chinese medicine |
||||||||||||||||||||||
|
研究疾病: |
屈光不正 |
||||||||||||||||||||||
|
Target disease: |
ametropia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
评价飞秒激光辅助制瓣角膜原位磨镶术联合快速角膜胶原交联术对薄角膜中高度近视散光患者术后安全性、有效性和可预测性进行评估。 |
||||||||||||||||||||||
|
Objectives of Study: |
Objective to evaluate the safety, efficacy and predictability of femtosecond laser-assisted keratoplasty combined with rapid corneal collagen crosslinking in patients with high-level myopic astigmatism in thin cornea. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
所有患者均采用以下方法:术前常规消毒、角膜表面麻醉,采用VisuMax飞秒激光系统(Carl Zeiss Meditec,德国)制作角膜瓣,激光频率500kHz,能量110nJ,厚度100μm,角膜瓣直径 8.1mm,边切角度90°。掀瓣器将角膜瓣掀开,应用SCHWIND AMARIS 1050RS准分子激光机根据屈光度不同行角膜基质层消融。用0.22%Vibex Xtra 核黄素(美国,Avedro 公司))浸润角膜基质床,浸泡时间70s,注意保护角膜瓣不要被核黄素浸润,采用40ml平衡盐溶液冲洗角膜基质床,复位角膜瓣。紫外线交联仪(KXL,美国Avedro公司)进行370nm紫外光连续照射角膜70s,照射强度30mW/cm2,总能量为 2.1J/ cm2。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
All patients were treated with the following methods: routine disinfection before surgery, corneal surface anesthesia, and the VisuMax femtosecond laser system (Carl Zeiss Meditec, Germany) was used to make corneal flaps with laser frequency of 500kHz, energy of 110nJ, and thickness of 100 μ m. The diameter of the corneal flap was 8.1 mm, and the cutting angle was 90 °. The flap opener was used to open the corneal flap, and the SCHWIND AMARIS 1050RS excimer laser was used to ablate the corneal stroma according to different diopter. Infiltrate the corneal stroma bed with 0.22% Vibex Xtra riboflavin (American, Avedro Company) for 70s, pay attention to protect the corneal flap from being infiltrated by riboflavin, wash the corneal stroma bed with 40ml balanced salt solution, and reset the corneal flap. Ultraviolet crosslinker (KXL, Avedro Company, USA) continuously irradiates the cornea with 370nm ultraviolet light for 70s, the irradiation intensity is 30mW/cm2, and the total energy is 2.1J/cm2. |
||||||||||||||||||||||
|
纳入标准: |
纳入标准:(1)年龄≥18岁;(2)术单纯近视或复性近视合并散光,最佳矫正视力≥0.8;(3)术前屈光度:球镜度-1.00~-11.00 D,柱镜度≤-5.00 D,屈光度数稳定2年以上;(4)中央角膜厚度大于460um,术后角膜基质厚度大于280um;(5)患者至少停戴2周以上软性接触镜、停戴8周以上硬性接触镜或停戴3~6个月角膜塑形镜者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria: age ≥ 18 years old; surgery simple myopia or refractory myopia with astigmatism, best corrected visual acuity ≥ 0.8; preoperative diopter: spherical mirror -1.00 ~ -11.00 D, cylindrical degree ≤ - 5. 00 D, the refractive power is stable for more than 2 years; the central corneal thickness is greater than 460um, the postoperative corneal stroma thickness is greater than 280um; the patient should stop wearing at least 2 weeks of soft contact lens, stop wearing hard contact lens for 8 weeks or stop wearing 3~6 Months Orthokeratology. |
||||||||||||||||||||||
|
排除标准: |
排除标准:(1)疑似圆锥角膜、已确诊圆锥角膜或其他角膜扩张疾病者;(2)眼部活动性炎症和感染;(3)角膜厚度无法满足设定的切削深度:中央角膜厚度<450μm,预期切削后角膜瓣下剩余角膜中央基质厚度<250μm;(4)中度干眼;(5)未控制的青光眼、影响视力的白内障;(6)未控制的全身结缔组织病及自身免疫性疾病;(7)焦虑、抑郁等精神症状。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: patients with eye diseases or eye surgery history; Patients with subclinical keratoconus; Scar constitution, immune disease or connective tissue disease; Have mental symptoms such as depression. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-05-01 00:00:00至 To 2024-01-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-05-10 00:00:00 至 To 2024-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由科室医生根据患者自身角膜条件,给予合理的手术方式建议,对于角膜形态不规则、厚度较薄等患者会充分进行术前谈话,建议常规LASIK术中联合快速角膜交联,最终决定权在患者。根据手术方式不同进行分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
According to the patient's own corneal conditions, the department doctor will give reasonable suggestions on the operation method. For patients with irregular corneal shape and thin cornea, preoperative talks will be fully conducted. It is recommended that rapid corneal cross-linking be combined during conventional LAS |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月公开原始数据,临床试验公共管理平台http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open the original data six months after the completion of the test, Resman: http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集病例记录表(Case Record Form, CRF)和手术前后相关检查均整合在电子病历记录中,二电子采集和管理系统(Electronic Data Capture, EDC)有医院信息可保管;所有原始数据可通过下面链接查看(https://pan.baidu.com/s/16_EZ_AN8eMXCPcZCDAbRVA) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The case record form (CRF) and relevant examinations before and after the operation are integrated into the electronic medical record, and the electronic data capture (EDC) has hospital information to keep; All raw data can be viewed through the following link( https://pan.baidu.com/s/16_EZ_AN8eMXCPcZCDAbRVA ) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |